Phagenesis

Phagenesis is a MedTech company developing a neurostimulation system (Phagenyx) to treat swallowing dysfunction (dysphagia). The system targets and restores neurological components of swallowing, addressing a significant unmet need for patients with brain injuries or those who have undergone prolonged mechanical ventilation. This innovative therapy offers improved patient recovery and reduced healthcare costs.

Funding Round: Series D

Funding Amount: $42M

Date: 04-Mar-2024

Investors: EQT Life Sciences, Sectoral, British Patient Capital, Northern Gritstone, Aphelion/Cardeation Capital

Markets: MedTech, Neurostimulation, Healthtech, Medical Device

HQ: Manchester, England, United Kingdom

Founded: 2007

Website: https://www.phagenesis.com/

LinkedIn: https://www.linkedin.com/company/phagenesis-ltd

Twitter: http://twitter.com/phagenesis

Instagram:

Facebook: https://www.facebook.com/phagenesis